查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1932157

分子影像CRO市場依顯像模式、應用、服務類型和最終用戶分類，全球預測（2026-2032年）

Molecular Imaging CRO Market by Imaging Modality, Application, Service Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，分子影像 CRO 市場價值將達到 32.4 億美元，到 2026 年將成長至 37 億美元，到 2032 年將達到 98.4 億美元，複合年成長率為 17.17%。

關鍵市場統計數據
基準年 2025 32.4億美元
預計年份：2026年 37億美元
預測年份 2032 98.4億美元
複合年成長率 (%) 17.17%

現代化的分子影像CRO能力、技術整合和營運需求介紹，旨在重塑臨床前和臨床影像工作流程。

分子影像技術融合了生物學、化學和臨床應用，能夠從分子和細胞層面精細地可視化疾病。近年來，硬體、探針化學和計算分析技術的進步拓展了影像技術在治療研發、轉化研究和臨床決策支援中的應用。因此，從學術研究機構到製藥公司，各方相關人員越來越依賴專業的受託研究機構來提供可重複、合規且高度精確的影像資料。

技術成熟度、放射性示蹤劑創新和數據驅動分析的融合，正在重新定義生命科學領域的分子影像研究和服務提供。

分子影像領域經歷了一系列變革，這些變革的驅動力包括技術成熟、監管要求不斷演變以及計算方法的融合。硬體創新提高了磁振造影（MRI）、正子斷層掃描（PET）、單光子發射電腦斷層掃描（SPECT）和光學平台的空間和時間解析度，使研究人員能夠在臨床前和臨床環境中提出更詳細的生物學問題。同時，放射性追蹤劑的化學性質也變得更加靈活，拓展了可成像標靶的多樣性，並加速了從藥物發現到首次人體試驗的轉化。

評估關稅變化對分子影像CRO營運的營運和供應鏈影響，以及維持研究連續性和資料完整性的策略

包括關稅調整和貿易措施在內的政策環境正在影響整個分子影像生態系統的營運規劃。關稅正在衝擊特種耗材、儀器零件和進口放射化學前驅物的供應鏈，迫使許多機構重新評估供應商多元化、庫存策略和採購區域。這些變化可能會延長關鍵試劑和組件的前置作業時間，因此制定緊急時應對計畫和加強與供應商的關係對於維持研究進度至關重要。

關鍵的細分洞察揭示了分子影像方式的選擇、臨床應用、服務模式和最終用戶需求如何共同影響專案設計和供應商選擇。

細分有助於系統地了解不同模式、應用程式、服務類型和最終用戶的需求促進因素、能力和服務匹配。從成像模式的角度來看，磁振造影 (MRI) 對於高解析度的解剖和功能終點評估至關重要，而光學成像（包括生物發光和螢光技術）則可提供快速且經濟高效的臨床前篩檢和機制闡明。正子斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT) 及其各自的臨床和臨床前亞類，有助於標靶結合評估和劑量測定，提供彌合轉化醫學差距的定量分子數據。

區域趨勢和基礎設施差異將決定成像能力、法規結構和協作網路將如何影響全球市場的專案執行。

區域趨勢影響著分子影像價值鏈中的技術能力、法規環境和合作模式。在美洲，強大的產學研合作和成熟的臨床試驗基礎設施支持著影像生物標記的快速轉化研究，而專業服務供應商提供與藥物研發需求相契合的廣泛的臨床前和臨床影像服務。這個生態系統正在推動PET和SPECT應用以及先進MRI通訊協定的創新。

策略性企業行動與能力差異化因素：定義分子影像合約研究市場的競爭格局、夥伴關係模式與價值提案

分子影像CRO領域的競爭者透過專注於專業技術、整合服務組合或地理覆蓋範圍來展現差異化策略。一些供應商強調端到端能力，將放射性示蹤劑開發、影像擷取和進階數據分析相結合，以最大限度地減少轉化阻力並提供承包工程。另一些供應商則專注於特定優勢領域，例如高通量光學成像平台或臨床PET/SPECT服務，並在特定領域憑藉速度和技術卓越性建立聲譽。

給領導者的具體建議：增強韌性，規範分析流程，並發展能夠加速轉化研究並滿足專案進度要求的綜合服務模式。

產業領導者應制定行動計劃，以增強韌性、加速轉換價值並提升競爭優勢。首先，應優先建構模組化服務架構，整合放射性示蹤劑開發、影像擷取和數據分析，同時讓客戶建構客製化的研究方案。這種方法可以減輕申辦者的負擔，並支持在各種研究設計中獲得可重複的結果。其次，應深化與供應商的關係，並對關鍵耗材和合成前驅物的替代來源進行評估，以降低供應鏈中斷和關稅帶來的風險。

結合專家訪談、能力初步分析和文獻綜述的穩健混合研究途徑，確保了研究結果的可操作性和可重複性。

本研究採用多維度方法，結合專家訪談、一手資料收集以及對技術、監管和營運文獻的系統性回顧。對影像科學家、放射化學家、臨床研究人員和服務營運經理的訪談，提供了關於成像方式選擇、示踪劑開發路徑以及不斷變化的終端用戶期望的定性見解。一手資料收集著重於不同類型服務供應商的服務產品、平台功能和夥伴關係模式，旨在了解各公司如何滿足特定影像方式和應用主導的需求。

本文全面探討如何策略性地整合影像技術專長、示蹤劑化學和分析技術，以促進轉化研究的成功和診斷影像專案的韌性。

總之，分子影像領域正朝著以品質主導的綜合服務方向發展，將影像技術專長、示蹤劑創新和分析技術融合在一起，以支持轉化醫學目標的實現。能夠將放射性示蹤劑開發、影像服務和先進數據分析相結合，同時保持健全品質系統的供應商，將更有能力滿足學術機構、受託研究機構、醫院和診斷中心以及製藥和生物技術贊助商的需求。隨著成像方式的不斷多樣化（例如，磁振造影、各種光學成像、臨床和臨床前正子斷層掃描、臨床和臨床前單光子發射電腦斷層掃描），成功的專案將取決於對成像方式的謹慎選擇和協調一致的分析流程。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依成像方式分類的分子影像CRO市場

  • MRI
  • 光學成像
    • 生物發光成像
    • 螢光影像
  • PET
    • 臨床PET
    • 臨床前PET
  • SPECT
    • 臨床SPECT
    • 臨床前SPECT

第9章 按應用分類的分子影像CRO市場

  • 心臟病學
    • 心臟衰竭影像學
    • 心肌灌注顯像
  • 發炎
    • 自體免疫疾病影像學
    • 感染疾病影像學
  • 神經病學
    • 阿茲海默症影像學
    • 帕金森氏症影像學
  • 腫瘤學
    • 血液腫瘤影像學
    • 固態腫瘤影像

第10章 分子影像CRO市場依服務類型分類

  • 數據分析
  • 影像服務
  • 放射性示踪劑的研發

第11章 分子影像CRO市場（依最終用戶分類）

  • 學術研究機構
  • 合約研究機構
  • 醫院和診斷中心
  • 製藥和生物技術公司

第12章 分子影像CRO市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 分子影像CRO市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國分子影像CRO市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國分子影像CRO市場

第16章：中國分子影像CRO市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ABX-CRO Advanced Pharmaceutical Services, LLC
  • Bioclinica, Inc.
  • Biomedical Systems Corporation
  • Biospective, Inc.
  • Biotrial, SA
  • Blue Earth Diagnostics Ltd.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Gubra A/S
  • ICON plc
  • Image Analysis Group, LLC
  • Imaging Endpoints, Inc.
  • IQVIA Holdings Inc.
  • Labcorp Drug Development, Inc.
  • Medpace Holdings, Inc.
  • Micron, Inc.
  • Oncodesign SA
  • Parexel International Corporation
  • Serac Life Sciences, Inc.
  • Tracer CRO, LLC
Product Code: MRR-7B550E008FB7

The Molecular Imaging CRO Market was valued at USD 3.24 billion in 2025 and is projected to grow to USD 3.70 billion in 2026, with a CAGR of 17.17%, reaching USD 9.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.24 billion
Estimated Year [2026] USD 3.70 billion
Forecast Year [2032] USD 9.84 billion
CAGR (%) 17.17%

A contemporary introduction to molecular imaging CRO capabilities, technological convergence, and the operational demands reshaping preclinical and clinical imaging workflows

Molecular imaging sits at the intersection of biology, chemistry, and clinical translation, enabling nuanced visualization of disease at molecular and cellular levels. Recent advances in hardware, probe chemistry, and computational analytics have expanded the applicability of imaging across therapeutic development, translational research, and clinical decision support. As a result, stakeholders from academic research institutes to pharmaceutical developers increasingly rely on specialized contract research organizations to deliver reproducible, compliant, and high-fidelity imaging data.

Within this environment, modalities such as MRI, Optical Imaging, PET, and SPECT play complementary roles. MRI provides rich anatomical and functional context, Optical Imaging - including bioluminescence and fluorescence techniques - accelerates preclinical screening and mechanistic studies, and PET and SPECT span preclinical and clinical workflows for quantitative molecular readouts. Consequently, organizations must align modality selection with study objectives, regulatory expectations, and downstream analytical requirements.

Given the complexity of modern imaging programs, service offerings now emphasize integrated solutions that include imaging services, radiotracer development, and advanced data analysis. These combined capabilities reduce time-to-insight and mitigate translational gaps. Looking forward, the field is positioned for continued convergence of imaging modalities with AI-driven analytics and purpose-built radiochemistry, shaping the way therapeutic candidates and diagnostics are evaluated across cardiology, neurology, inflammation, and oncology applications

How technological maturation, radiotracer innovation, and data-driven analytics are converging to redefine molecular imaging research and service delivery in life sciences

The landscape of molecular imaging has undergone a series of transformative shifts driven by technological maturation, evolving regulatory expectations, and the integration of computational methods. Hardware innovation has improved spatial and temporal resolution across MRI, PET, SPECT, and optical platforms, enabling investigators to ask more granular biological questions across both preclinical and clinical settings. At the same time, radiotracer chemistry has become more agile, expanding the diversity of targets that can be imaged and accelerating transitions from discovery to first-in-human evaluation.

Parallel to hardware and chemistry advances, data analytics has emerged as a core competency. Sophisticated image processing, quantitative modeling, and machine learning approaches now uncover subtle signal patterns and support biomarker qualification. This analytical evolution elevates the role of data analysis services, which complement imaging services and radiotracer development to offer end-to-end solutions. Moreover, these changes are influencing how end users-academic research institutes, contract research organizations, hospitals and diagnostic centers, and pharmaceutical biotech-structure collaborations, outsource capabilities, and define success metrics.

Additionally, cross-modality strategies are more common, with hybrid study designs leveraging the anatomical context of MRI, the sensitivity of PET and SPECT in both clinical and preclinical formats, and the rapid throughput of bioluminescence and fluorescence optical imaging. These convergent strategies, combined with stricter reproducibility standards and demand for regulatory-grade data, are compelling providers to adopt standardized pipelines, robust quality systems, and transparent reporting frameworks that support multi-stakeholder decision-making

Assessing the operational and supply chain ramifications of tariff changes on molecular imaging CRO operations and strategies to preserve study continuity and data integrity

The policy environment, including tariff adjustments and trade measures, influences operational planning across the molecular imaging ecosystem. Tariffs affect supply chains for specialized consumables, instrumentation components, and imported radiochemistry precursors, leading many organizations to reassess supplier diversification, inventory strategies, and sourcing geographies. In turn, these shifts can extend lead times for critical reagents and parts, necessitating contingency planning and stronger vendor relationships to sustain study timelines.

As a consequence, service providers have revised procurement practices and prioritized local supplier development where feasible. This transition often involves qualifying alternate vendors, increasing stock levels for key items, and collaborating closely with equipment manufacturers to secure maintenance and spare parts. For radiotracer development, changes in precursor availability have prompted laboratories to explore alternative synthetic routes and to invest in modular synthesis platforms that offer greater flexibility under constrained supply conditions.

Moreover, tariff-driven cost pressures are encouraging providers and end users to examine the full cost structure of imaging programs, identifying opportunities to increase operational efficiency without compromising data quality. Increased attention to platform standardization, assay harmonization, and remote data processing helps offset some of these pressures. Ultimately, a strategic response to tariff impacts emphasizes resilience through diversified sourcing, flexible workflows, and strengthened supplier partnerships to protect study continuity and scientific integrity

Key segmentation insights that reveal how modality choices, clinical applications, service types, and end-user needs collectively shape program design and vendor selection in molecular imaging

Segmentation provides a structured way to understand demand drivers, capabilities, and service alignment across modalities, applications, service types, and end users. When analyzed through the lens of imaging modality, MRI remains essential for high-resolution anatomical and functional endpoints, while optical imaging-comprising bioluminescence and fluorescence techniques-delivers rapid, cost-effective preclinical screening and mechanistic insights. PET and SPECT, each with clinical and preclinical subdivisions, serve as quantitative molecular readouts that bridge translational gaps and support target engagement and dosimetry assessments.

Looking at application domains, cardiology studies focused on heart failure imaging and myocardial perfusion imaging require distinct protocols, tracer selection, and analytical pipelines compared with inflammation workstreams addressing autoimmune imaging and infection imaging. Neurology programs centered on Alzheimer's imaging and Parkinson's imaging demand rigorous longitudinal designs, sensitive radiotracers, and harmonized imaging endpoints. Oncology efforts span hematological tumor imaging and solid tumor imaging, each presenting unique biodistribution, microenvironmental, and tracer uptake considerations that shape study design and interpretation.

Service type segmentation highlights the interdependence of imaging services, radiotracer development, and data analysis. Integrated offerings that combine high-quality imaging acquisition with bespoke tracer chemistry and robust quantitative analytics enable more reliable biomarker readouts. Finally, end-user segmentation-encompassing academic research institutes, contract research organizations, hospitals and diagnostic centers, and pharmaceutical biotech-illuminates purchasing behavior, regulatory expectations, and preferred engagement models, informing how providers position their capabilities and structure collaborations

Regional dynamics and infrastructure differences that determine how imaging capabilities, regulatory frameworks, and collaborative networks influence program execution across global markets

Regional dynamics influence capabilities, regulatory contexts, and collaboration models across the molecular imaging value chain. In the Americas, robust academic-industrial partnerships and a mature clinical trial infrastructure support rapid translation of imaging biomarkers, while specialist service providers deliver a wide range of preclinical and clinical imaging services that align with pharmaceutical development needs. This ecosystem fosters innovation in PET and SPECT applications as well as advanced MRI protocols.

In Europe, the Middle East & Africa, regulatory harmonization efforts and strong research networks underpin collaborative multicenter studies, and hospitals and diagnostic centers often serve as hubs for early clinical imaging programs. Academic research institutes contribute foundational science, and contract research organizations operate as integrators of modality-specific expertise and centralized analytics. Across this combined region, radiotracer development benefits from dense networks of radiochemistry facilities and cross-border collaborations.

The Asia-Pacific region continues to expand its capacity across imaging modalities and service types, driven by increased investment in healthcare infrastructure and growing pharmaceutical and biotech activity. Local manufacturers, growing numbers of academic research institutes, and an expanding community of clinical imaging centers are enabling more regionalized study execution. Together, these regional distinctions highlight how geography informs supply chain decisions, regulatory engagement, and partner selection for imaging programs

Strategic company behaviors and capability differentiators that define competition, partnership models, and value propositions within the molecular imaging contract research market

Companies competing in the molecular imaging CRO space demonstrate differentiated strategies by concentrating on specialized modality expertise, integrated service portfolios, or geographic coverage. Some providers emphasize end-to-end capabilities, combining radiotracer development, imaging acquisition, and advanced data analysis to minimize translational friction and deliver turnkey programs. Others focus on niche strengths such as high-throughput optical imaging platforms or clinical PET/SPECT services, building reputations for speed and technical excellence in targeted segments.

Strategic partnerships and alliances are common, enabling firms to extend their service reach without diluting core competencies. Collaboration between radiochemistry specialists and imaging centers, for example, facilitates access to novel tracers while maintaining compliance with clinical manufacturing standards. At the same time, investment in digital infrastructure and analytics capabilities distinguishes companies that can provide standardized, regulatory-grade outputs and support multi-site harmonization.

Operationally, leading organizations place emphasis on quality management systems, reproducible protocols, and transparent reporting to meet the expectations of pharmaceutical biotech sponsors and academic consortia. This focus on reliability, combined with flexible engagement models, positions select providers as preferred partners for complex translational projects and late-stage development programs

Actionable recommendations for leaders to build resilience, standardize analytics, and craft integrated service models that accelerate translation and protect program timelines

Industry leaders should pursue an action agenda that strengthens resilience, accelerates translational value, and enhances competitive differentiation. First, prioritize modular service architectures that integrate radiotracer development, imaging acquisition, and data analysis while allowing clients to assemble tailored study packages. This approach reduces friction for sponsors and supports reproducible outcomes across varied study designs. Second, deepen supplier relationships and qualify alternate sources for critical consumables and synthesis precursors to mitigate supply chain disruptions and tariff-driven risks.

Third, invest in analytics platforms and standardized processing pipelines that support cross-site harmonization and regulatory readiness. Demonstrating consistent, validated quantitative outputs will increasingly become a discriminator in partner selection. Fourth, expand collaborative networks with academic research institutes and hospital centers to accelerate access to patient populations, novel biomarkers, and platform validation opportunities. Finally, adopt flexible commercial models that align with client needs, including modular pricing, data access options, and advisory services to support study design and regulatory engagement. Collectively, these actions position organizations to deliver higher-value programs, preserve study continuity under changing trade conditions, and capture demand across diverse application areas

A robust mixed-methods research approach combining expert interviews, primary capability mapping, and literature synthesis to ensure actionable and reproducible insights

This research draws upon a multidimensional methodology that combines expert interviews, primary data collection, and a structured review of technological, regulatory, and operational literature. Interviews with imaging scientists, radiochemists, clinical investigators, and service operations leaders provided qualitative perspectives on modality selection, tracer development pathways, and the evolving expectations of end users. Primary data collection focused on service offerings, platform capabilities, and partnership models across provider types to map how firms address modality-specific and application-driven requirements.

Complementing qualitative inputs, the approach included systematic review of recent peer-reviewed studies, technical white papers, and publicly available regulatory guidance to ensure that interpretations reflect contemporary standards for image acquisition, quantitation, and clinical validation. Emphasis was placed on reproducibility, methodological transparency, and harmonization practices in multi-site studies. Triangulation of sources ensured that conclusions were grounded in convergent evidence and practical experience, while iterative validation with industry practitioners refined the framing of service models and recommended operational strategies

Concluding perspective on the strategic integration of modality expertise, tracer chemistry, and analytics to drive translational success and program resilience in imaging

In summary, the molecular imaging landscape is evolving toward integrated, quality-driven service delivery where modality expertise, tracer innovation, and analytics converge to support translational objectives. Providers that combine radiotracer development, imaging services, and advanced data analysis while maintaining robust quality systems will be best positioned to meet the needs of academic research institutes, contract research organizations, hospitals and diagnostic centers, and pharmaceutical biotech sponsors. As modalities continue to diversify-spanning MRI, optical imaging variants, clinical and preclinical PET, and clinical and preclinical SPECT-successful programs will rely on deliberate modality selection and harmonized analytical pipelines.

Regional differences underscore the importance of local partnerships and supply chain strategies, and policy changes affecting tariffs reinforce the need for procurement resilience and operational flexibility. Ultimately, organizations that adopt modular service models, invest in validated analytics, and cultivate strategic collaborations will accelerate translational impact and protect study timelines amid changing market conditions. Continued emphasis on reproducibility, regulatory alignment, and transparent reporting will further elevate the role of specialized imaging CROs in supporting therapeutic and diagnostic innovation

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Imaging CRO Market, by Imaging Modality

  • 8.1. MRI
  • 8.2. Optical Imaging
    • 8.2.1. Bioluminescence Imaging
    • 8.2.2. Fluorescence Imaging
  • 8.3. PET
    • 8.3.1. Clinical PET
    • 8.3.2. Preclinical PET
  • 8.4. SPECT
    • 8.4.1. Clinical SPECT
    • 8.4.2. Preclinical SPECT

9. Molecular Imaging CRO Market, by Application

  • 9.1. Cardiology
    • 9.1.1. Heart Failure Imaging
    • 9.1.2. Myocardial Perfusion Imaging
  • 9.2. Inflammation
    • 9.2.1. Autoimmune Imaging
    • 9.2.2. Infection Imaging
  • 9.3. Neurology
    • 9.3.1. Alzheimer's Imaging
    • 9.3.2. Parkinson's Imaging
  • 9.4. Oncology
    • 9.4.1. Hematological Tumor Imaging
    • 9.4.2. Solid Tumor Imaging

10. Molecular Imaging CRO Market, by Service Type

  • 10.1. Data Analysis
  • 10.2. Imaging Services
  • 10.3. Radiotracer Development

11. Molecular Imaging CRO Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Centers
  • 11.4. Pharmaceutical Biotech

12. Molecular Imaging CRO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Molecular Imaging CRO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Molecular Imaging CRO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Molecular Imaging CRO Market

16. China Molecular Imaging CRO Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ABX-CRO Advanced Pharmaceutical Services, LLC
  • 17.6. Bioclinica, Inc.
  • 17.7. Biomedical Systems Corporation
  • 17.8. Biospective, Inc.
  • 17.9. Biotrial, SA
  • 17.10. Blue Earth Diagnostics Ltd.
  • 17.11. Charles River Laboratories International, Inc.
  • 17.12. Crown Bioscience, Inc.
  • 17.13. Gubra A/S
  • 17.14. ICON plc
  • 17.15. Image Analysis Group, LLC
  • 17.16. Imaging Endpoints, Inc.
  • 17.17. IQVIA Holdings Inc.
  • 17.18. Labcorp Drug Development, Inc.
  • 17.19. Medpace Holdings, Inc.
  • 17.20. Micron, Inc.
  • 17.21. Oncodesign SA
  • 17.22. Parexel International Corporation
  • 17.23. Serac Life Sciences, Inc.
  • 17.24. Tracer CRO, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLECULAR IMAGING CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MOLECULAR IMAGING CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY FLUORESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY FLUORESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY FLUORESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEART FAILURE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEART FAILURE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEART FAILURE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MYOCARDIAL PERFUSION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MYOCARDIAL PERFUSION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MYOCARDIAL PERFUSION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY AUTOIMMUNE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY AUTOIMMUNE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY AUTOIMMUNE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFECTION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFECTION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFECTION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ALZHEIMER'S IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ALZHEIMER'S IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ALZHEIMER'S IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PARKINSON'S IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PARKINSON'S IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PARKINSON'S IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEMATOLOGICAL TUMOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEMATOLOGICAL TUMOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEMATOLOGICAL TUMOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SOLID TUMOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SOLID TUMOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SOLID TUMOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY RADIOTRACER DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY RADIOTRACER DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY RADIOTRACER DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 214. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 215. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 261. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 262. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 263. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)